Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases

被引：133

作者：

Tanaka, Toshio ^{[2
]}

Narazaki, Masashi ^{[2
]}

Kishimoto, Tadamitsu ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Frontier Biosci, Immunoregulat Lab, Suita, Osaka 5650871, Japan

[2] Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, Suita, Osaka 5650871, Japan

来源：

FEBS LETTERS | 2011年 / 585卷 / 23期

关键词：

Tocilizumab; A humanized anti-IL-6 receptor antibody; IL-6; Autoimmune diseases; Inflammation; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ENDOTHELIAL GROWTH-FACTOR; ONSET STILLS-DISEASE; SERONEGATIVE SYMMETRICAL SYNOVITIS; MODIFYING ANTIRHEUMATIC DRUGS; RHEUMATOID-ARTHRITIS PATIENTS; SIGNAL-TRANSDUCING RECEPTOR; SERUM CYTOKINE PROFILES; CENTRAL-NERVOUS-SYSTEM; SOLUBLE IL-6 RECEPTOR;

D O I：

10.1016/j.febslet.2011.03.023

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Interleukin (IL)-6 is a cytokine with multiple biological activities. It contributes to host defense against pathogens, whereas accelerated production of IL-6 plays a significant pathological role in various diseases. Clinical trials have demonstrated the efficacy of tocilizumab, a humanized anti-IL-6 receptor antibody, for patients with rheumatoid arthritis, Castleman's disease or juvenile idiopathic arthritis, leading to approval of this innovative drug for the treatment of these diseases. Since IL-6 has been demonstrated to play a significant role in the development of various other autoimmune and inflammatory diseases, tocilizumab can be expected to become a novel drug for such diseases as well. (C) 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

引用

页码：3699 / 3709

页数：11

共 157 条

[1]

Toll-like receptor signalling [J].

Akira, S ;

Takeda, K .

NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) :499-511

[2]

Interleukin 6 is required for the development of collagen-induced arthritis [J].

Alonzi, T ;

Fattori, E ;

Lazzaro, D ;

Costa, P ;

Probert, L ;

Kollias, G ;

De Benedetti, F ;

Poli, V ;

Ciliberto, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (04) :461-468

[3]

Circulating cytokines in active polymyalgia rheumatica [J].

Alvarez-Rodriguez, L. ;

Lopez-Hoyos, M. ;

Mata, C. ;

Jose Marin, M. ;

Calvo-Alen, J. ;

Blanco, R. ;

Aurrecoechea, E. ;

Ruiz-Soto, M. ;

Martinez-Taboada, V. M. .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (01) :263-269

[4]

RS3PE syndrome presenting as vascular endothelial growth factor associated disorder [J].

Arima, K ;

Origuchi, T ;

Tamai, M ;

Iwanaga, N ;

Izumi, Y ;

Huang, M ;

Tanaka, F ;

Kamachi, M ;

Aratake, K ;

Nakamura, H ;

Ida, H ;

Uetani, M ;

Kawakami, A ;

Eguchi, K .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (11) :1653-1655

[5]

Ankylosing spondylitis [J].

Braun, Juergen ;

Sieper, Joachim .

LANCET, 2007, 369 (9570) :1379-1390

[6]

Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists [J].

Brulhart, Laure ;

Nissen, Michael J. ;

Chevallier, Paola ;

Gabay, Cem .

JOINT BONE SPINE, 2010, 77 (06) :625-626

[7]

Campbell L., 2010, RHEUMATOLOGY

[8]

A look at autoimmunity and inflammation in the eye [J].

Caspi, Rachel R. .

JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (09) :3073-3083

[9]

Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis [J].

Cid, MC ;

Hernández-Rodríguez, J ;

Esteban, MJ ;

Cebrián, M ;

Gho, YS ;

Font, C ;

Urbano-Márquez, A ;

Grau, JM ;

Kleinman, HK .

CIRCULATION, 2002, 106 (13) :1664-1671

[10]

Cimmino MA, 2008, CLIN EXP RHEUMATOL, V26, P395

← 1 2 3 4 5 6 7 8 9 10 →